Acute Kidney Injury, Depression
Conditions
Keywords
antidepressants, acute kidney injury, SNRI, renal failure, duloxetine, CNODES
Brief summary
The purpose of this study is to determine if there is an excess risk of acute kidney injury (AKI) with Serotonin-norepinephrine reuptake inhibitors (SNRIs) as compared to Selective serotonin reuptake inhibitors (SSRIs), two classes of medication used for the treatment of depression.
Detailed description
We plan to conduct retrospective population-based cohort studies within eight administrative databases from Canada, the United States, and the United Kingdom. Within each cohort, a nested case-control analysis will be performed to estimate incidence rate ratios (RR) of AKI associated with SNRIs compared to SSRIs using conditional logistic regression, with adjustment for high-dimensional propensity scores at baseline. The overall effect across sites will then be estimated using meta-analytic methods.
Interventions
DRUGDuloxetine
Current exposure to Duloxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
DRUGVenlafaxine
Current exposure to Venlafaxine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
DRUGDesvenlafaxine
Current exposure to Desvenlafaxine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
DRUGCitalopram
Current exposure to Citalopram will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
DRUGEscitalopram
Current exposure to Escitalopram will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
DRUGFluoxetine
Current exposure to Fluoxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
DRUGFluvoxamine
Current exposure to Fluvoxamine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
DRUGParoxetine
Current exposure to Paroxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
DRUGSertraline
Current exposure to Sertraline will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
Sponsors
Drug Safety and Effectiveness Network, Canada
Canadian Institutes of Health Research (CIHR)
Canadian Network for Observational Drug Effect Studies, CNODES
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* A first prescription of an antidepressant of the SNRI or SSRI class of any dose between January 1, 1997 and March 31, 2010.
Exclusion criteria
* They were \<12 years old at the time of cohort entry. * They had less than 1 year of information in the database prior to the date of cohort entry. * They had a prescription of an SNRI or SSRI in the year before the date of cohort entry. * They had a prescription for both an SNRI and an SSRI on the day of cohort entry. * They had a history of chronic kidney disease (including kidney transplantation and dialysis) or AKI in the year preceding cohort entry. * The subject was previously included in the cohort.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Acute Kidney Injury (AKI) | 2 years | AKI will be defined as patients hospitalized with one of the following diagnosis codes for AKI in any of the listed diagnoses: ICD-9-CM codes 584, 584.5, 584.6, 584.7, 584.8, or 584.9; ICD-10 N17, N17.0, N17.1, N17.2, N17.8, or N17.9. |
Countries
Canada
Outcome results
None listed